Research of Helmsley Center for Electrophysiology at The Mount Sinai Hospital
Mount Sinai's Leona M. and Harry B. Helmsley Charitable Trust Center for Cardiac Electrophysiology is a world leader in cardiac arrhythmia research, investigating new technologies and novel techniques to make our therapies safer and more effective. We are the lead center for a number of large clinical trials. This gives our patients access to the most advanced arrhythmia treatments available. Some highlights of our research activities include the following:
- Atrial Fibrillation: Treatments for atrial fibrillation aim to reduce the burden of atrial fibrillation and prevent its most devastating complication—stroke. Mount Sinai is at the forefront of testing new technologies for atrial fibrillation ablation. Our doctors have also done pioneering research on the Watchman device - a small mesh device which is placed inside the heart to prevent stroke in patients with atrial fibrillation.
- Ventricular Tachycardia: Ablation of ventricular tachycardia is a very complex procedure. We are participating in multiple clinical trials investigating safer and more effective ways to perform this procedure.
- Renal Denervation: Renal sympathetic denervation has recently been shown to be effective for treatment of hypertension that is not easily treated with medications. The procedure works, at least in part, by decreasing the adrenaline response (sympathetic tone) throughout the body. This helps to decrease blood pressure, and some data suggests that it may also be beneficial for cardiac arrhythmias. The Mount Sinai team has forged new techniques for performing renal denervation. We are conducting FDA-authorized research using this procedure for treatment of refractory hypertension and cardiac arrhythmias.
- Pacemakers, ICDs, and Devices for Heart Failure: Mount Sinai will be the lead center for the U.S. trial of a new Leadless Cardiac Pacemaker, which is set to begin in 2014. We were also involved in the study which gained FDA approval for the subcutaneous ICD. As of October 2013, Mount Sinai is the only center in the New York City area performing subcutaneous ICD implants. New devices are also being tested for the treatment of congestive heart failure.